A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT05254743 · RECRUITING
Trial details
- NCT number
- NCT05254743
- Sponsor
- Loxo Oncology, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-22
- Primary completion
- 2027-10-01
- Enrollment
- 737
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.